These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 32296931)
1. Flaxseed and/or hesperidin supplementation in metabolic syndrome: an open-labeled randomized controlled trial. Yari Z; Cheraghpour M; Hekmatdoost A Eur J Nutr; 2021 Feb; 60(1):287-298. PubMed ID: 32296931 [TBL] [Abstract][Full Text] [Related]
2. The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial. Yari Z; Cheraghpour M; Alavian SM; Hedayati M; Eini-Zinab H; Hekmatdoost A Eur J Clin Nutr; 2021 Jan; 75(1):99-111. PubMed ID: 32647367 [TBL] [Abstract][Full Text] [Related]
3. The effects of flaxseed supplementation on metabolic syndrome parameters, insulin resistance and inflammation in ulcerative colitis patients: An open-labeled randomized controlled trial. Morshedzadeh N; Rahimlou M; Shahrokh S; Karimi S; Mirmiran P; Zali MR Phytother Res; 2021 Jul; 35(7):3781-3791. PubMed ID: 33856729 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy of flaxseed and hesperidin enhances the effectiveness of lifestyle modification in cardiovascular risk control in prediabetes: a randomized controlled trial. Yari Z; Naser-Nakhaee Z; Karimi-Shahrbabak E; Cheraghpour M; Hedayati M; Mohaghegh SM; Ommi S; Hekmatdoost A Diabetol Metab Syndr; 2021 Jan; 13(1):3. PubMed ID: 33402222 [TBL] [Abstract][Full Text] [Related]
5. Flaxseed Supplementation in Metabolic Syndrome Management: A Pilot Randomized, Open-labeled, Controlled Study. Yari Z; Rahimlou M; Poustchi H; Hekmatdoost A Phytother Res; 2016 Aug; 30(8):1339-44. PubMed ID: 27151322 [TBL] [Abstract][Full Text] [Related]
6. The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. Yari Z; Movahedian M; Imani H; Alavian SM; Hedayati M; Hekmatdoost A Eur J Nutr; 2020 Sep; 59(6):2569-2577. PubMed ID: 31844967 [TBL] [Abstract][Full Text] [Related]
7. The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial. Haidari F; Banaei-Jahromi N; Zakerkish M; Ahmadi K Nutr J; 2020 Jan; 19(1):8. PubMed ID: 31980022 [TBL] [Abstract][Full Text] [Related]
8. The Effects of Flaxseed Oil Omega-3 Fatty Acids Supplementation on Metabolic Status of Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Mirmasoumi G; Fazilati M; Foroozanfard F; Vahedpoor Z; Mahmoodi S; Taghizadeh M; Esfeh NK; Mohseni M; Karbassizadeh H; Asemi Z Exp Clin Endocrinol Diabetes; 2018 Apr; 126(4):222-228. PubMed ID: 29117618 [TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of the effects of flaxseed lignan complex on metabolic syndrome composite score and bone mineral in older adults. Cornish SM; Chilibeck PD; Paus-Jennsen L; Biem HJ; Khozani T; Senanayake V; Vatanparast H; Little JP; Whiting SJ; Pahwa P Appl Physiol Nutr Metab; 2009 Apr; 34(2):89-98. PubMed ID: 19370038 [TBL] [Abstract][Full Text] [Related]
10. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia. Wong H; Chahal N; Manlhiot C; Niedra E; McCrindle BW JAMA Pediatr; 2013 Aug; 167(8):708-13. PubMed ID: 23733031 [TBL] [Abstract][Full Text] [Related]
11. Clinical and metabolic response to flaxseed oil omega-3 fatty acids supplementation in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. Soleimani Z; Hashemdokht F; Bahmani F; Taghizadeh M; Memarzadeh MR; Asemi Z J Diabetes Complications; 2017 Sep; 31(9):1394-1400. PubMed ID: 28716357 [TBL] [Abstract][Full Text] [Related]
12. Flaxseed supplementation improves anthropometric measurements, metabolic, and inflammatory biomarkers in overweight and obese adults. Yari Z; Rahimlou M; Poustchi H; Hekmatdoost A Int J Vitam Nutr Res; 2022 Jul; 92(3-4):161-168. PubMed ID: 30843767 [No Abstract] [Full Text] [Related]
13. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Yari Z; Rahimlou M; Eslamparast T; Ebrahimi-Daryani N; Poustchi H; Hekmatdoost A Int J Food Sci Nutr; 2016 Jun; 67(4):461-9. PubMed ID: 26983396 [TBL] [Abstract][Full Text] [Related]
14. Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials. Mohammadi-Sartang M; Sohrabi Z; Barati-Boldaji R; Raeisi-Dehkordi H; Mazloom Z Nutr Rev; 2018 Feb; 76(2):125-139. PubMed ID: 29228348 [TBL] [Abstract][Full Text] [Related]
15. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial. Ursoniu S; Sahebkar A; Andrica F; Serban C; Banach M; Clin Nutr; 2016 Jun; 35(3):615-25. PubMed ID: 26071633 [TBL] [Abstract][Full Text] [Related]
16. The Effect of Hesperidin and Diosmin Individually or in Combination on Metabolic Profile and Neuropathy among Diabetic Patients with Metabolic Syndrome: A Randomized Controlled Trial. Osama H; Hamed EO; Mahmoud MA; Abdelrahim MEA J Diet Suppl; 2023; 20(5):749-762. PubMed ID: 35946912 [TBL] [Abstract][Full Text] [Related]
17. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial. Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718 [TBL] [Abstract][Full Text] [Related]
18. The HYPERFlax trial for determining the anti-HYPERtensive effects of dietary flaxseed in newly diagnosed stage 1 hypertensive patients: study protocol for a randomized, double-blinded, controlled clinical trial. Caligiuri SP; Penner B; Pierce GN Trials; 2014 Jun; 15():232. PubMed ID: 24938224 [TBL] [Abstract][Full Text] [Related]
19. Effects of flaxseed and flaxseed oil supplement on serum levels of inflammatory markers, metabolic parameters and severity of disease in patients with ulcerative colitis. Morshedzadeh N; Shahrokh S; Aghdaei HA; Amin Pourhoseingholi M; Chaleshi V; Hekmatdoost A; Karimi S; Zali MR; Mirmiran P Complement Ther Med; 2019 Oct; 46():36-43. PubMed ID: 31519285 [TBL] [Abstract][Full Text] [Related]